| Title | Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance |
| Publication Type | Journal Article |
| Year of Publication | 2009 |
| Authors | Sahin O, Fröhlich H, Löbke C, Korf U, Burmester S, Majety M, Mattern J, Schupp I, Chaouiya C, Thieffry D, Poustka A, Wiemann S, Beissbarth T, Arlt D |
| Journal | BMC systems biology |
| Volume | 3 |
| Pagination | 1 |
| Date Published | 2009 |
| ISSN | 1752-0509 |
| Keywords | Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Blotting, Western, Breast Neoplasms, Cell Line, Tumor, Computer Simulation, DNA-Binding Proteins, Drug Delivery Systems, Female, G1 Phase, Humans, Models, Biological, Protein Engineering, Receptor, Epidermal Growth Factor, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction, Transcription Factors |
| Abstract | In breast cancer, overexpression of the transmembrane tyrosine kinase ERBB2 is an adverse prognostic marker, and occurs in almost 30% of the patients. For therapeutic intervention, ERBB2 is targeted by monoclonal antibody trastuzumab in adjuvant settings; however, de novo resistance to this antibody is still a serious issue, requiring the identification of additional targets to overcome resistance. In this study, we have combined computational simulations, experimental testing of simulation results, and finally reverse engineering of a protein interaction network to define potential therapeutic strategies for de novo trastuzumab resistant breast cancer. |
| Alternate Journal | BMC Syst Biol |